Abstract
Hepatic encephalopathy (HE) is a common problem after insertion of a trans-jugular intrahepatic portosystemic shunt (TIPS), which may be difficult to manage. We present a case of severe post-TIPS HE unresponsive to high doses of l-ornithine-l-aspartate (LOLA) despite reduction of venous ammonia levels in a dose-dependent fashion. Ultimately, high-grade HE was successfully treated by a reduction stent and the patient subsequently underwent successful liver transplantation.
Similar content being viewed by others
Abbreviations
- HE:
-
hepatic encephalopathy
- TIPS:
-
transjugular intrahepatic portosystemic shunt
- LOLA:
-
l-ornithine-l-aspartate
References
Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328:1046–1052
Blei AT, Olafsson S, Therrien G, Butterworth RF (1994) Ammonia-induced brain edema and intracranial hypertension in rats after portacaval anastomosis. Hepatology 19:1437–1444
Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72:573–583
Cordoba J, Dupuis J, Gottstein J, Blei AT (1997) Stenosis of a portacaval anastomosis affects circadian locomotor activity in the rat: A multivariable analysis. Am J Physiol 273:G1218–G1225
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716–721
Fleig WE, Kircheis G, Spengler U, Zeuzem ST, Gortelmeyer R, The German-Austrian-Swiss Multicenter Study Group (1999) Placebo-controlled, double-blind evaluation of L-ornithine–L-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (HE). J Hepatol 30:65 (abstract)
Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodes J (2002) Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123:1839–4187
Hauenstein KH, Haag K, Ochs A, Langer M, Rossle M (1995) The reducing stent: treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure. Radiology 194:175–179
Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R, Hendricks R, Kruger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rosch W, Stauch S (1997) Therapeutic efficacy of l-ornithine-l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 25:1351–1360
Klempnauer J, Schrem H (2001) Review: surgical shunts and encephalopathy. Metab Brain Dis 16:21–25
Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger S (1996) Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial French Group of Clinicians and a Group of Biologists. J Hepatol 25:135–144
Leonhardt H, Bungert HJ (1972) Therapie der schweren Hyperammoniaemie. Med Klin 67:1052–1056
Lozeva V, Montgomery JA, Tuomisto L, Rocheleau B, Pannunzio M, Huet PM, Butterworth RF (2004) Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 40:742–748
Luca A, D’Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L (1999) TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology 212:411–421
Madoff DC, Wallace MJ, Ahrar K, Saxon RR (2004) TIPS-related hepatic encephalopathy: Management options with novel endovascular techniques. Radiographics 24:21–36
Ochs A, Rossle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, Huonker M, Langer M, Blum HE (1995) The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 332:1192–1197
Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB (2002) Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 36:1163–1171
Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villarreal L, Zozaya JM, Betes M, Herrero JI, Prieto J (1995) Transjugular intrahepatic portal systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 21:986–994
Riggio O, Merli M, Pedretti G, Servi R, Meddi P, Lionetti R, Rossi P, Bezzi M, Salvatori F, Ugolotti U, Fiaccadori F, Capocaccia L (1996) Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt Incidence and risk factors. Dig Dis Sci 41:578–584
Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF (1998) L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: Therapeutic efficacy and mechanism of action. Metab Brain Dis 13:147–57
Rose C, Michalak A, Rao, KV, Quack G, Kircheis G, Butterworth RF (1999) L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 30:636–640
Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, Spahr L, Huet PM, Pomier-Layrargues G (1999) Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 117:640–644
Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL (2000) A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342:1701–1707
Saab S, Nieto J, Ly, D, Runyon B (2004) TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 3:CD004889
Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, Nicolini A, Salvatori F (2004) Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40:629–635
Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T (2003) North American study for the treatment of refractory ascites group the North American study for the treatment of refractory ascites. Gastroenterology 124:634–641
Somberg KA, Riegler JL, LaBerge JM, Doherty-Simor MM, Bachetti P, Roberts JP, Lake JR (1995) Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: Incidence and risk factors. Am J Gastroenterol 90:549–555
Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Gortelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rosch W, Steffens J (1998) Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo-controlled double-blind study. J Hepatol 28:856–864
Ter Borg PC, Hollemans M, Van Buuren HR, Vleggaar FP, Groeneweg M, Hop WC, Lameris JS (2004) Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3–9 years. Radiology 231:537–545
Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L (1995) Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 122:816–822
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stadlbauer, V., Tauss, J., Portugaller, H.R. et al. Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): Management with l-ornithine-l-aspartate and stent reduction. Metab Brain Dis 22, 45–50 (2007). https://doi.org/10.1007/s11011-006-9032-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-006-9032-3